logo

For the Inventor, By the Inventor

Newbury Park, CA, United States of America

Kexue Li

LinkedIn

This inventor holds 19 USPTO granted patents and 13 published patent applications and 9 EPO patents, primarily in Cancer Therapeutics. Top assignees: Amgen Inc., Japan Tobacco Inc.. Active years: 2007-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kexue Li. Retrieved from https://idiyas.com/inventor/kexue-li

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 

% Patents Active = 89.5

 

Average Co-Inventor Count = 8.9

ph-index = 5

Forward Citations = 49(Granted Patents)


Location History:

  • Palo Alto, CA (US) (2007)
  • Mountain View, CA (US) (2007 - 2015)
  • Thousand Oaks, CA (US) (2020 - 2022)
  • Newbury Park, CA (US) (2019 - 2024)

Company Filing History:

goldMedal17 out of 2,072 
 
Amgen Inc.
 patents
silverMedal2 out of 1,067 
 
Japan Tobacco Inc.
 patents

Years Active: 2007-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
KIF18A Inhibitors
MCL-1 Protein
Macrocyclic Compounds
Cell Cycle Inhibitors
Fused Pyridine Compounds
Fused Bicyclic Heterocycles
Gem-Disubstituted Amino Pyridines
Spirocyclic Pyrimidines
19 patents (USPTO):Explore Patents
1. 12509442 - KIF18A inhibitors (2025-12-30),
2. 12459932 - KIF18A inhibitors (2025-11-04),
3. 12441736 - KIF18A inhibitors (2025-10-14),
4. 12441705 - KIF18A inhibitors (2025-10-14),
5. 12091425 - Compounds that inhibit MCL-1 protein (2024-09-17),
6. 12054476 - KIF18A inhibitors (2024-08-06),
7. 11364248 - Compounds that inhibit Mcl-1 protein (2022-06-21),
8. 11306107 - Compounds that inhibit MCL-1 protein (2022-04-19),
9. 11279712 - Macrocyclic compounds that inhibit MCL-1 protein (2022-03-22),
10. 11224601 - Compounds that inhibits MCL-1 protein (2022-01-18),
11. 10821115 - Compounds that inhibit Mcl-1 protein (2020-11-03),
12. 10632128 - Compounds that inhibit Mcl-1 protein (2020-04-28),
13. 10500213 - Compounds that inhibit Mcl-1 protein (2019-12-10),
14. 10300075 - Compounds that inhibit MCL-1 protein (2019-05-28),
15. 8980903 - Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors (2015-03-17),

Title: Kexue Li: Innovator in Cancer Treatment

Introduction

Kexue Li is a prominent inventor based in Newbury Park, California, known for his significant contributions to the field of cancer research. With a total of 18 patents to his name, he has made remarkable strides in developing innovative treatments for cancer and cancer-related diseases.

Latest Patents

Among his latest patents are the KIF18A inhibitors, which include compounds capable of modulating the KIF18A protein. This modulation influences the processes of cell cycle and cell proliferation, providing potential therapeutic avenues for treating cancer. The invention encompasses pharmaceutical compositions that include these compounds and methods for treating disease states related to KIF18A activity.

Career Highlights

Kexue Li has had a distinguished career, working with notable companies such as Amgen Inc. and Japan Tobacco Inc. His work has been pivotal in advancing cancer treatment methodologies, showcasing his dedication to improving patient outcomes through innovative research.

Collaborations

Throughout his career, Kexue Li has collaborated with various professionals in the field, including Sean P Brown and Yunxiao Li, who is a woman. These collaborations have further enriched his research and development efforts.

Conclusion

Kexue Li's contributions to cancer treatment through his innovative patents and collaborations highlight his role as a leading inventor in the medical field. His work continues to inspire advancements in cancer therapies and improve the lives of many patients.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…